This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Romani, A. Articles by Cosi, V. Search for Related Content PubMed PubMed Citation Articles by Romani, A. Articles by Cosi, V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 4-AMINOPYRIDINE FLUOXETINE Social Bookmarking                         What's this?

Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment

Laboratorio Potenziali Evocati, Istituto Neurologico ‘C. Mondino’, Pavia, Italy, alfredo.romani{at}mondino.it

Roberto Bergamaschi

Dipartimento di Scienze Neurologiche, Università di Pavia, Pavia, Italy

Elisa Candeloro

Dipartimento di Scienze Neurologiche, Università di Pavia, Pavia, Italy

Enrico Alfonsi

Servizio di Neurofisiopatologia, Istituto Neurologico ‘C. Mondino’, Pavia, Italy

Roberto Callieco

Laboratorio Potenziali Evocati, Istituto Neurologico ‘C. Mondino’, Pavia, Italy

Vittorio Cosi

Dipartimento di Scienze Neurologiche, Università di Pavia, Pavia, Italy

Sixty relapsing-remitting multiple sclerosis (MS) patients were selected on the basis of their score on the Fatigue Severity Scale (FSS) and formed two groups: 40 patients (fatigued MS; MSf) scored above the 75th percentile of a previously assessed representative MS sample (100 patients), and 20 age- and sex-matched patients (nonfatigued MS patients; MSnf) scored below the 25th percentile. The patients underwent clinical evaluation (Expanded Disability Status Scale (EDSS)), further assessment of fatigue (Fatigue Impact Scale), scales evaluating depression (Hamilton Depression Rating Scale (HDRS) and Beck’s Depression Inventory (BDI)) and neuropsychological tests. All patients were evaluated for muscle fatigability and central activation by means of a biomechanical test of sustained contraction; they also underwent somatosensory evoked potentials (SSEPs) and transcranial magnetic stimulation (TMS). The patients of the MSf subgroup were then randomized to one of the following two treatments: 4-aminopyridine (4-AP) 24 mg/day and fluoxetine (FLX) 20 mg/day. After a one-week titration this treatment proceeded for 8 weeks. At the end of the treatment, EDSS, fatigue and depression scores were further evaluated. At baseline, fatigue test scores consistently correlated with depression and cognitive test scores, but not with the fatigability test. Fatigue scores decreased in both treatment groups in a similar way. Due to the design of the study, this cannot be disjoined from a placebo effect. The changes of fatigue scores could not be predicted in the FLX group, whereas in the 4-AP group higher basal fatigability test scores were associated with greater reduction in fatigue scores.

Key Words: 4-aminopyridine • evoked potentials • fatigability • fluoxetine • fatigue • multiple sclerosis • transcranial magnetic stimulation

Multiple Sclerosis, Vol. 10, No. 4, 462-468 (2004)
DOI: 10.1191/1352458504ms1051oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. S. Haussleiter, M. Brune, and G. Juckel Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 13 - 29. [Abstract] [PDF]

				C Lebrun, H Alchaar, M Candito, V Bourg, and M Chatel Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue Multiple Sclerosis, June 1, 2006; 12(3): 321 - 324. [Abstract] [PDF]

				D E J Jones, N Bhala, J Burt, J Goldblatt, M Prince, and J L Newton Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort Gut, April 1, 2006; 55(4): 536 - 541. [Abstract] [Full Text] [PDF]